



6

\$162
#7
7/16/01
C. S. L.

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

RECEIVED

**RESPONSE TO RESTRICTION
REQUIREMENT AND REQUEST FOR
EXTENSION OF TIME PURSUANT TO 37
C.F.R. § 1.136(a)**

Docket Number:
1662/49502

JUL 12 2001

TECH CENTER 1600/2900

Application Number
09/552,485

Filing Date
April 18, 2000

Examiner
Bernhardt, E.

Art Unit
1624

Invention Title
**NOVEL SYNTHESIS AND CRYSTALLIZATION OF
PIPERAZINE RING-CONTAINING COMPOUNDS
[MIANSERIN]**

Inventor(s)
SINGER et al.

Address to:
Assistant Commissioner for Patents
Washington D.C. 20231

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on

Date: July 5, 2001

Reg. No. 35,539

Signature: Paul Johnson

Sir:

Transmitted herewith is a Response to Restriction Requirement for entry in the above-identified application:

1. Applicant respectfully requests a five-month extension of time in which to respond to the Restriction Requirement dated January 5, 2001, for which a response period expiring on February 5, 2001 was set. The extended period expires on July 5, 2001. The Commissioner is hereby authorized to charge payment of the 37 C.F.R. § 1.136(a) extension fee of **\$1,890.00** to the deposit account of **Kenyon & Kenyon**, deposit account number **11-0600**.
2. The filing fee has been calculated after entry of the accompanying Response as shown below:

RECEIVED

JUL 12 2001

	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT NUMBER EXTRA	RATE (\$)	TECH CENTER FEE (\$)
TOTAL CLAIMS	41	minus	28	13	18.00	234.00
INDEPENDENT CLAIMS	7	minus	4	3	80.00	240.00
MULTIPLE DEPENDENT CLAIM ADDED					270.00	0
				TOTAL		474.00
				SMALL ENTITY TOTAL		

3. Please charge the required additional claims fee of **\$474.00** to deposit account number **11-0600**

4. The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to the deposit account of **Kenyon & Kenyon**, deposit account number **11-0600**:
 - A. Any additional filing fees required under 37 C.F.R. § 1.16;
 - B. Any additional patent application processing fees under 37 C.F.R. § 1.17;
 - C. Any additional patent issue fees under 37 C.F.R. § 1.18;
 - D. Any additional document supply fees under 37 C.F.R. § 1.19;
 - E. Any additional post-patent processing fees under 37 C.F.R. § 1.20; or
 - F. Any additional miscellaneous fees under 37 C.F.R. § 1.21.

5. A duplicate copy of this letter is enclosed.

Dated: July 5, 2001

By: Paul Johnson
Paul Johnson (Reg. No. 35,559)

KENYON & KENYON
One Broadway
New York, N.Y. 10004
(212) 425-7200 (telephone)
(212) 425-5288 (facsimile)



#81A
7/16/01
C. Style

PATENT
Docket No. 1662/49502

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

Inventor : Singer, et al.
Serial No. : 09/552,485
Filing Date : April 18, 2000
For: : Novel Synthesis and Crystallization of Piperazine
Ring-Containing Compounds [Mianserin]
Examiner : Bernhardt, E.
Art Unit : 1624

JUL 12 2001

TECH CENTER 1600/2900

Assistant Commissioner for Patents
Washington D.C. 20231

I hereby certify that this correspondence is being sent by
facsimile addressed to: Assistant Commissioner for Patents,
Washington, D.C. 20231 on

Date: July 5, 2001

Reg. No. 35,559

Signature: Paul Johnson

RESPONSE TO RESTRICTION REQUIREMENT

This amendment is responsive to the Office Action dated January 5, 2001 in the above-captioned application. Applicants hereby request a five-month extension of time for responding to the Requirement for Restriction mailed January 5, 2001, for which a one-month response period was set. The extended period expires on July 5, 2001. The Commissioner is authorized to charge payment of the 37 C.F.R. § 1.136(a) extension fee, or any additional required fees, to the deposit account of Kenyon & Kenyon, deposit account number 11-0600.

In response to the Office Action dated January 5, 2001, setting forth a restriction requirement, Applicants elect the subject matter of Group IV, drawn to "mirtazapine and composition and use."